Background {#Sec1}
==========

Neutrophil elastase {#Sec2}
-------------------

Neutrophils play a key role in the pathogenesis of numerous diseases, ranging from chronic inflammatory disorders to infectious diseases and neoplasms \[[@CR1]\]. Their role in the innate immune system mainly consists in extracellular phagocytosis, involving reactive oxygen species, cationic proteins, and enzymes. Several granules are sequentially formed in neutrophil cytoplasm, differing in their propensity for exocytosis, according to their biosynthesis timing. Granules formed at a later stage of differentiation shows a higher secretory potential than those formed in immature myeloid cells, such as the azurophilic granules containing myeloperoxidase, defensins, and proteinases. Neutrophils live shortly in the blood of healthy individuals (around 8 h), but following inflammatory conditions they become activated and their longevity may increase up to 5 days. The prolonged life of neutrophils leads to functional changes and contributes to the inflammatory-associated morbidity shown in bronchiectasis patients \[[@CR2]\].

Once inflammatory trigger develops in peripheral tissues, neutrophils are rapidly recruited toward to the anatomical site of inflammation. Their migration out of the blood stream involves endothelial attachment and rolling along the endothelium, activation, adhesion, and, finally, trans-endothelial extravasation into the *interstitium*. The neutrophilic inflammatory response depends on the degranulation of pre-formed mediators from cytoplasmatic granules and on the ability to generate respiratory burst activity via reactive oxygen species system. Although they ontogenetically play key functions in antimicrobial defense, their activation can also damage host cells and tissues. Neutrophil degranulation is responsible for the release of several inflammatory mediators, such as neutrophil elastase, cathepsin G, and proteinase 3 \[[@CR3]\].

Human neutrophil elastase (NE) is a proteolytic enzyme belonging to the chymotrypsin-like family of the serine-proteinases. NE is a 218 aminoacid long protein packaged in cytoplasmatic azurophilic granules in neutrophil granulocytes \[[@CR4]\]. Though NE is mainly involved in the response against bacteria, it can cause several detrimental effects, including extracellular matrix destruction, mucus gland hyperplasia and increased mucus production, reduction of ciliary beating rate, and direct damage to the airway epithelium \[[@CR5]--[@CR7]\]. The acid *milieu* within granules protects the cell from proteolytic activity. Upon neutrophil activation, degranulation is triggered by the mild alkalosis resulting from the fusion between the granules and cytoplasmic phagosomes containing engulfed bacteria \[[@CR8]\]. In addition to this intracellular pathway, NE is also liberated into the extracellular space, both free and membrane-bound. High concentrations of soluble NE participate in bacterial killing at the site of degranulation and in a small area around the cell. More distantly, activated enzymes are completely neutralized by proteinase inhibitors. On the other hand, membrane-bound NE is remarkably resistant to inhibition by the anti-proteinase system, thus preserving its proteolytic activity. Overexpression of this mechanism has the potential to cause tissue damage \[[@CR9]\].

During neutrophil activation, NE-containing granules also translocate from the cytoplasm to the nucleus, where it is involved in the degradation of chromatin by splitting histones. Then, neutrophils disintegrate and release neutrophil extracellular traps (NETs). Although this remains a controversial or fully unexplored area, this process is hypothesized to facilitate the neutralization of pathogens, including bacteria, fungi, and protozoa. NETs are networks of extracellular fibers, composed of DNA bound to histone proteins and neutrophil proteinases. NE is the most common non-histone protein in NETs \[[@CR10]\].

A complex interaction among proteases and anti-proteases is required for an effective respiratory immune system. Lower airways in patients with neutrophil elastase-mediated lung diseases are characterized by an excess of proteases leading to tissue destruction and lung function decline. A1AT is the most abundant anti-protease within the lung and the major inhibitor of NE. A1AT is encoded by the SERPINA1 gene located on the long arm of chromosome 14 and produced mainly by hepatocytes and, to a lesser extent, by alveolar macrophages. Imbalance between NE and A1AT may be due to either an A1AT deficiency, as documented in COPD and emphysema, or unopposed NE activity, as proved in CF and bronchiectasis \[[@CR11]\]. In the latter context, NE shows the ability to combine with polyanions (such as DNA or glycosaminoglycans) and syndecan-1 becoming inaccessible and limiting its inactivation by A1AT \[[@CR12]\].

Besides NE, the serine protease group also includes cathepsin G (Cat G) and proteinase 3 (PR3), which are also stored in high concentrations in the azurophil granules within the neutrophil cytoplasm \[[@CR4]\]. Cat G is a 235-amino acid protein released during the neutrophil activation process. Intracellularly, Cat G is released within the phagosome to degrade engulfed pathogens; extracellularly, it contributes to the degradation of structural ECM components and other immune mediators \[[@CR13]\]. PR3 is a 222-amino acid long serine protease encoded by the PRTN3 gene and expressed by activated neutrophils. Its biological function is similar to that of NE. In particular, PR3 is responsible for proteolytic degradation and activation of IL-8 in a truncated peptide with fostered chemoattractant effect towards neutrophils.

NE determination assays {#Sec3}
-----------------------

Different techniques have been used for NE determination. Both ready to use commercial kits and in-home assays are useful for in vitro quantitative determination of NE. The three most used techniques are ELISA \[[@CR14]\], fluorimetric \[[@CR15]\] and spectrophotometric \[[@CR16]\] methods. In Table [1](#Tab1){ref-type="table"} some example of NE determination assays is provided showing different samples, types of measurement and detection ranges.Table 1Neutrophil elastase determination assaysNameSamplesType of measurementAssayUnit of measureN° of testDetection rangeLimit of detectionHuman Elastase ELISA (Hycult Biotech)Plasma, Cell culture supernatantActive NEELISAng/mL2 × 960.4--25 ng/mL0.4 ng/mLProteaseTag® Active NE Immunoassay (ProAxsis Ltd)BAL, Sputum sol, Serum free mediaActive NEELISAng/mL9615.625--1000 ng/mL7.2 ng/mLHuman PMN Elastase ELISA Kit (Abcam)Cell culture supernatant, Serum, PlasmaPMN Elastase/alpha1-PI complexELISAng/mL960.16--10 ng/ml1.98 pg/mLNeutrophil elastase Human ELISA Kit, CE (eBioscience)Cell culture supernatant, Serum, PlasmaPMN Elastase/alpha1-PI complexELISAng/mL960.16--10.0 ng/mL1.98 pg/mLNeutrophil Elastase Activity Assay Kit (Abcam)Plasma, Whole Blood, Purified proteinActive NEFluorometricng1001--25 ng1 ngDynatech MR 5000 (Dynatech Corporation)Sputum solActive NESpectrophotometrymcgM96----Neutrophil Elastase Activity Assay Kit (Cayman Chemical)BloodActive NEFluorometricmU/mL2 × 960--10 mU/mL0.156 mU/mLDefinitions: *NE* neutrophil elastase, *alpha1-PI* alpha-1 proteinase inhibitor; *PMN* polymorphonuclear leukocytes

NE can be detected by two different methods: the assessment of NE ability to proteolytically cleave a synthetic substrate (qualitative measurement); and the quantification of human NE concentrations in different biological *media* (quantitative measurement). Both the detection of the active enzyme and the measurement of the amount of enzyme bound to its inhibitor, alpha-1 antitrypsin (A1AT), are techniques currently used to measure NE in biological samples.

When ELISA assays are employed, the wells in a microtiter plate are coated with a specific antibody able to bind NE. ProteaseTag® is a quantitative method to dose NE activity using NE-Tag and the subsequent antibody step provides additional signal amplification with increased sensitivity with good results in a recent study conducted by Chalmers \[[@CR17]\].

Fluorimetric and spectrophotometric assays are based on the ability of NE to proteolytically cleave a synthetic substrate causing the release of a fluorophore or a change in optical density, respectively, which can be quantified by fluorescence or absorbance microplate readers. Standard curves are obtained for both methods and concentration of samples can be determined from curve interpretation.

Commercial kits may also be used to quantify NE in plasma, serum, cell-culture supernatant, bronchoalveolar lavage (BAL), sputum, or whole blood. Among other methodologies, elastin agarose diffusion plate for measurement of elastolytic activity has been also reported in previous literature \[[@CR18]\].

Elastin degradation as a consequence of NE activity results in the presence of elastin-derived peptides, including desmosine and isodesmosine in serum, plasma and urine. Both separation based on high performance liquid chromatography/mass spectrometry and radioimmunoassay are validated techniques for the detection of iso- and desmosine in body fluids \[[@CR19], [@CR20]\]. Finally, high-performance capillary electrophoresis has been applied to the study of proteases \[[@CR21]\].

Neutrophil elastase in chronic respiratory diseases {#Sec4}
===================================================

Cystic fibrosis {#Sec5}
---------------

An outburst of neutrophilic inflammation characterizes CF patients and it is associated with high concentrations of neutrophil proteases, including NE. NE has several implications in inflammation in CF, although a comprehensive summary of NE effects is not in the purpose if this review NE has an important role in the pathogenesis of lung inflammation in CF even in the absence of any infections. High levels of both NE and IL-8 have been demonstrated in BAL of infants with CF \[[@CR22]\]. A recent study by Sly showed a correlation between NE activity in BAL from CF children and the early development of bronchiectasis \[[@CR23]\].

NE is a potent upregulator of several inflammatory chemokines, such as IL-8 and MMP-9, leading to a self-perpetuating cycle of neutrophilic inflammation with several detrimental effects \[[@CR24]\]. Firstly, NE impairs ciliary beating and promotes expression of respiratory tract mucins (MUC5AC and MUC5B), resulting in muco-ciliary clearance failure \[[@CR7], [@CR25]\]. Secondly, NE-dependent structural damage against elastin and other pulmonary components leads to the irreversible airway dilation and early bronchiectasis development. Thirdly, NE can degradate lactoferrin, an important anti-microbial glycoprotein as well as several molecules involved in pathogens' opsonization \[[@CR26]--[@CR29]\]. Furthermore, NE can cause impairment of lymphocytic function by degradation of T-cell surface receptors and interfere with the process of antigen presentation by dendritic cells \[[@CR30], [@CR31]\]. The sum of all these mechanisms leads to the paradox of an overstimulated immune system unable to effectively kill colonizing pathogens.

Finally, NE may directly affect the ion transport in CF cells acting as a potent activator of silent ENaC channels causing increased Na absorption and further airway surface dehydration and muco-ciliary dysfunction \[[@CR32]\]. In a recent study, Le Gars and coworkers illustrated that high NE levels lead to CFTR loss of function via activation of intracellular calpains that are directly responsible for the proteolytic degradation of CFTR \[[@CR33]\].

Treatments targeted against NE have been evaluated in CF patients. AZD9668, a reversible oral inhibitor of NE, when administered 60 mg twice daily orally for 4 weeks, showed no effect on sputum neutrophil counts, NE activity, lung function or clinical outcomes, but a consistent pattern of reduction in sputum inflammatory biomarkers and a significant decrease of free and total urine desmosine were reported in a double-blind randomized controlled trial (RCT) enrolling \~60 CF patients \[[@CR34]\]. A phase-II clinical trial assessed the efficacy of inhaled A1AT, with significant reduction of NE activity and inflammatory biomarker expression without any effects on lung function \[[@CR35]\]. The limited efficacy observed with both AZD9668 and A1AT in CF patients could be mainly ascribed to the fact that the studies were most likely too short and not powered to investigate disease-modifying effects.

Chronic obstructive pulmonary disease {#Sec6}
-------------------------------------

In patients with COPD neutrophils in sputum correlate with severity of disease in terms of FEV~1~ decline and peripheral airway dysfunction identified by high-resolution computed tomography \[[@CR36]\]. Several studies highlighted that cigarette smoke and lung pollutants activate macrophages and epithelial cells triggering the release of neutrophil chemotactic factors \[[@CR37], [@CR38]\]. In this context NE is a major determinant of tissue damage. A landmark study on COPD-related lung tissue by Damiano showed a positive correlation between the distribution of NE within alveolar spaces and the presence of emphysema \[[@CR39]\]. Instillation of human NE has been shown to induce emphysema in the animal model, while Shapiro and coworkers demonstrated that mice deficient for NE expression were protected from the development of emphysematous changes \[[@CR40], [@CR41]\]. More recently, Paone have found that elevated levels of NE in COPD in both sputum and BAL highly correlated with severity of disease and lung function decline \[[@CR42]\].

Treatment strategies targeting NE have been proposed also for patients with COPD. AZD9668 was shown to slow lung function decline and dampen the inflammatory burden \[[@CR43]\]. However, two RCTs which recruited symptomatic COPD patients exposed to AZD9668 for 12 weeks failed to show any clinical efficacy nor beneficial effects on inflammatory biomarker expression \[[@CR44], [@CR45]\]. This lack of efficacy may be due to inappropriate study design in term of patients selection, relevant dose, duration of treatment and endpoints assessments. It has been recently demonstrated that in a subpopulation with alpha1-antitrypsin (A1AT) deficiency, intravenous administration of A1AT slowed the loss of lung parenchyma \[[@CR46]\].

Asthma {#Sec7}
------

Chronic inflammation in asthma is highly heterogeneous. Although in the past asthma was thought as a mere Th2-mediated inflammatory response to inhaled antigens, neutrophils and their products have recently been considered to play a role during both stable conditions and exacerbations \[[@CR47], [@CR48]\]. Simpson and colleagues showed that neutrophilic asthma is characterized by higher concentrations of active NE, generating the hypothesis that anti-proteases may be beneficial in the treatment of asthmatic patients \[[@CR49]\]. At the current state, no studies on NE inhibitors in patients with asthma are currently available.

Neutrophil Elastase in Bronchiectasis {#Sec8}
=====================================

Bronchiectasis is defined as an abnormal and permanent dilation of the bronchi associated with daily cough, sputum production, and recurrent respiratory infections \[[@CR50]\]. The prevalence of bronchiectasis has risen during the last decade both in hospital and community settings owing to population aging, as well as widespread use of chest CT scan and more awareness of the disease \[[@CR50], [@CR51]\]. The pathophysiology of bronchiectasis is not completely understood, particularly in view of the heterogeneity of the disease and the absence of an animal model \[[@CR52]\]. A fundamental role is played by both impaired mucus clearance and chronic bacterial infections leading to a serious neutrophilic activation by the release of chemotactic mediators. A recent study by Dente and coworkers demonstrated that sputum neutrophils in bronchiectasis patients correlated with worse pulmonary function, bacterial colonization, and severe disease \[[@CR53]\]. In this context, NE is a key determinant of tissue damage and a potential marker of both disease severity and activity, a predictor of long-term clinical outcomes, and a treatment target. In order to better evaluate the role of NE in bronchiectasis, a systematic search of scientific evidence on NE in bronchiectasis was performed.

Methods {#Sec9}
=======

Search methodology {#Sec10}
------------------

Two investigators (AG and FA) independently performed the search on PubMed and assessed the studies according to predefined criteria. Reference lists of the selected manuscripts were also manually assessed. English language restriction was applied. This systematic revision was conducted according to PRISMA statement \[[@CR54]\].

### Study selection {#Sec11}

We included studies published up to May 15, 2017. Key terms included: 'bronchiectasis AND neutrophilic elastase OR neutrophil elastase'; 'bronchiectasis AND protease'; 'bronchiectasis AND neutrophil elastase inhibitors'; 'bronchiectasis AND desmosine'. After literature search, titles and abstracts were reviewed by two independent investigators (AG and FA) and in case of disagreement a final decision was taken by the principal investigator (SA). Articles were excluded if: (1) written in languages other than English; (2) they were case reports, case series, or qualitative reviews; (3) NE was not measured; (4) missing bronchiectasis patients; (5) inclusion of CF patients; (6) inclusion of pediatric patients; (7) full-text was unavailable. Full-text was finally obtained for selected papers.

### Data extraction and analysis {#Sec12}

After the full-text analysis, data of interest from each included paper were extracted. Data of interest included: name of the first author, year of publication, study design, sample size, assay manufacturer, biological *matrix*, setting, clinical state of patients, quantitative findings and endpoints. Corresponding authors were contacted if data were not present or unclear in the full-text. Given the high degree of heterogeneity across papers taken into account, a meta-analysis was not performed.

Results {#Sec13}
=======

The process and results of the search are shown in Fig. [1](#Fig1){ref-type="fig"}. The majority of the selected studies were rejected because either they were qualitative reviews or case series (*n* = 35) or not dealing with bronchiectasis patients (*n* = 34), or evaluating CF patients (*n* = 29) /children (*n* = 5), or their full-text was not available in English (*n* = 16). A final pool of 31 studies was included in the systematic review, with a total of 2679 patients (Table [2](#Tab2){ref-type="table"}). Selected papers were published from 1984 to 2016, with an elevated frequency in the period 1998--2002 (10/31, 32.3%). The majority had a cross-sectional design (19/31, 61.3%). Only six (19.4%) studies included patients during an acute exacerbation. Measurement of NE was highly heterogeneous, including both commercial kits and in-home assays. Sputum was the most represented biological sample for NE detection. Blood samples were occasionally collected for NE or desmosine measurement \[[@CR17], [@CR21], [@CR55]\]. Only one (3.2%) study detected urine desmosine. Most of the selected studies were aimed to assess NE as an inflammatory marker (19/31, 61.3%), while 7 (22.6%) studies investigated NE as a marker of response to treatment and 1 (3.2%) study evaluated NE as a target of therapy.Fig. 1Flow-chart of the systematic review Table 2Results of the systematic reviewAuthor and yearStudy designSettingClinical stabilitySample sizeAssay manufacturer (methods)Quantitative findingsBiological *matrix*Major resultsStockley, 1984 \[[@CR18]\]Cross-sectionalMonocentric, outpatientsStable state\
Exacerbation34 Bx patientsElastin-agarose diffusion plate (in-home assay)NE activity (μg x mL): grade1 19.5; grade2 48.2; grade3 62.9SputumCorrelation with sputum macroscopic appearanceSmallman, 1984 \[[@CR6]\]Cross-sectional/ProspectiveMonocentric, outpatientsStable state8 Bx patientsElastin-agarose diffusion plate (in-home assay)NE activity (μg x mL): not quantified but evaluated as present/not present (lower limit of detection 0.8)SputumInverse correlation with ciliary beat frequency\
NE reduction after short-term antibiotic therapyFujita, 1992 \[[@CR60]\]Cross-sectionalMonocentric, outpatientsStable state9 Bx patients in a cohort of 64 chronic respiratory diseases +15 healthy subjectsElisa for NE- A1AT complex (in-home assay)NE-A1AT complex levels (μg x L): 558 ± 198; healthy subjects 122 ± 4BloodNE- A1AT complex higher in Bx patients than in healthy subjectsLloberes, 1992 \[[@CR63]\]Cross- sectionalMonocentric, outpatientsStable state26 Bx patientsElastin-agarose diffusion plate (in-home assay)NE activity (μg × 100 μL): purulent 7.75 (0--21.5); mucopurulent 1.3 (0--19.5); mucoid 0SputumCorrelation with sputum macroscopic appearanceIp, 1993 \[[@CR71]\]ProspectiveMonocentric, outpatientsExacerbation12 Bx patientsSpectrophotometry, SLAPN substrateNE activity (mU × 100 μL): baseline 50.5 ± 17.1; exacerbation before atb 51.8 ± 25.4; 1-week atb −24.3 ± 20.7; 2-week atb −35.1 ± 17.8; 2-week after atb −12.1 ± 35.6; 6-week after atb −32.8 ± 26.8SputumNE reduction after short-term antibiotic therapyLlewellyn-Jones, 1995 \[[@CR15]\]ProspectiveMonocentric, outpatientsStable state9 Bx patients +8 healthy subjectsFluorescence (in-home assay)NE activity (μg x mL^−1^): day -7th 4.0 ± 0.46; baseline 4.15 ± 0.69; day 14th 4.25 ± 0.63; day 28th 4.39 ± 0.65; day 63th 4.03 ± 0.67BloodNo NE reduction after indomethacinSepper, 1995 \[[@CR74]\]Cross-sectionalMonocentric, outpatientsStable state24 Bx patients +15 healthy subjectsSpectrophotometry, SAAVNA substrateNE activity (mU x g): mild group 0.21 ± 0.09; moderate group 1.87 ± 1.12; severe group 2.64 ± 1.63; healthy subjects 0.09 ± 0.03BALCorrelation with symptoms, exacerbation rate and radiological severityNakamura, 1997 \[[@CR56]\]Cross-sectionalMonocentric, outpatientsStable state3 Bx patients in a cohort of 8 chronic respiratory diseases +15 healthy subjectsElisa (in-home assay)Quantitative findings only reported as figuresBALNE higher in Bx than in healthy subjectsGaga, 1998 \[[@CR57]\]Cross-sectionalMonocentric, outpatientsStable state12 Bx patients +11 healthy subjectsImmunocitochemistry (in-home assay)Neutrophils (cells x mm^3^): Bx patients 114; healthy subjects 41Bronchial biopsiesNE higher in Bx than in healthy subjectsNakamura, 1999 \[[@CR78]\]ProspectiveMonocentric, outpatientsStable state3 Bx patients in a cohort of 10 chronic respiratory diseasesElisa (in-home assay)NE levels (μg x mL^−1^): baseline 125.5 ± 47.5; 16.8 ± 7.1 after atbBALNe reduction after 3-month roxithromycinIchikawa, 1999 \[[@CR64]\]Cross-sectionalMonocentric, outpatientsStable state18 Bx patients in a cohort of 59 chronic respiratory diseases +28 healthy subjectsSpectrofluorometry AMC substrateNE activity (U): purulent 1239.2 ± 1017.8; mucoid 45.7 ± 115.1SputumInverse correlation with IgBF levels and sputum purulenceHill, 2000 \[[@CR16]\]Cross- sectionalMonocentric, outpatientsStable state43 Bx patients in a cohort of 160 chronic respiratory diseasesSpectrophotometryNE levels (nM): mixed flora 0 (0--20); high bacterial load 21 (4--40)SputumCorrelation with sputum bacterial loadSchaaf, 2000 \[[@CR68]\]Cross-sectionalMonocentric, outpatientsStable state11 Bx patients in a cohort of 66 chronic respiratory diseases +12 healthy subjectsImmunoluminometry\
ColorimetryNE-A1AT complex levels (ng x mL): Bx patients 44 (15--152); healthy subjects 3 (0--15)BALNE higher in Bx than in healthy subjects\
Correlation with *P. aeruginosa* chronic respiratory infectionTsang, 2000 \[[@CR75]\]Cross-sectionalMonocentric, outpatientsStable state30 Bx patientsSpectrophotometry, SAAVNA substrateNE levels (U x mL): 6.60 ± 3.13SputumCorrelation with 24 h sputum volume, sputum inflammatory markers (leukocytes, IL-B and TNFa), radiological severity and spirometry (FEV~1~, FVC)Zheng, 2000 \[[@CR69]\]Cross-sectionalMonocentric, outpatientsStable state35 Bx patients +18 healthy subjectsSpectrophotometry, SAAVNA substrateNE levels (Unit x mL^−1^): P. aeruginosa 222.6 (18.3--267.5); 8.7 (0.6--186.7)SputumCorrelation with *P. aeruginosa* chronic respiratory infectionViglio, 2000 \[[@CR21]\]Cross-sectionalMonocentric, outpatientsStable state13 Bx patients in a cohort of 54 chronic respiratory diseases +24 healthy subjectsHPCEDES (μg x g creatinine^−1^): Bx patients 23.39 ± 2.05; CF 23.39 ± 2.02; A1AT deficiency 22.3 ± 7.74; exacerbated COPD 17.15 ± 3.42; stable COPD 14.17 ± 2.33; smokers 11.97 ± 2.75; healthy subjects 9.31 ± 2.75UrineDesmosine higher in stable Bx than in other chronic respiratory disease and healthy subjectsAngrill, 2001 \[[@CR62]\]Cross-sectionalMonocentric, outpatientsStable state49 Bx patients +9 healthy subjectsImmunoassay (?)NE levels (μg x L): colonized patients 231 (15--2930); not colonized patients 45 (8--2280); healthy subjects 34 (9--44)BALNE higher in Bx than in healthy subjects\
Correlation with neutrophils, IL8 and TNFa in BALF\
Correlation with bacterial chronic respiratory infection.Stockley, 2001 \[[@CR65]\]Cross-sectionalMonocentric, outpatientsStable state14 Bx patients +9 smokersSpectrophotometry, MSAPN substrate\
Elisa (in-home assay)NE levels (μM): sputum colour value-3 0.006 ± 1.0; sputum colour value-7 4.14 ± 1.0SputumCorrelation with sputum macroscopic appearance\
Correlation with MPO and 24 h sputum volume\
Inverse correlation with A1ATZheng, 2001 \[[@CR59]\]Cross-sectionalMonocentric, outpatientsStable state14 Bx patients +15 healthy subjectsAnti-NE antibodiesMedian neutrophils x mm^−2^: Bx patients 608 (101--1013); healthy subj. 127 (24--630)Endobronchial biopsiesNE higher in bronchiectatic lamina propria than in healthy subjectsVandivier, 2002 \[[@CR58]\]ProspectiveMonocentric, outpatientsExacerbation6 Bx patients in a cohort of 18 chronic respiratory diseasesSpectrophotometryNE (U x mL): Bx patients 10; CF 3SputumNE higher in Bx\
NE as cause of delay in apoptotic cell clearanceChan, 2003 \[[@CR12]\]Cross-sectionalMonocentric, outpatientsStable state10 Bx patientsSpectrophotometryNE activity range (mM): 0.9--1.2SputumNE not only as free but complexed with polyanionic partners (syndecan-1) and A1ATWatt, 2004 \[[@CR72]\]ProspectiveMonocentric, outpatientsExacerbation15 Bx patients +10 healthy subjectsKinetic assays (?)NE levels (ng x mL): after atb −73,451 (135,495--12,303)SputumNE reduction after short-term antibiotic therapyChan, 2009 \[[@CR61]\]Cross-sectionalMonocentric, outpatientsStable state12 Bx patientsSpectrophotometry, MSAPN substrate\
ELISA (in-home assay)NE activity (mM): 1.3 (1--2)SputumNE complexed with syndecan-1\
Description of protease/anti-protease balanceMurray, 2010 \[[@CR77]\]RCTMonocentric, outpatientsStable state65 Bx patientsElastin-agarose diffusion plate (in-home assay)NE activity gentamicin group vs placebo: (U x mg): baseline 3.6 (0--17.6) vs 4.1 (0--19); 3-month 0 (0--0) vs 0 (0--20.4); 6-month 0 (0--2.9) vs 0 (0--29.1); 9-month 0 (0--7.6) vs 0.9 (0--19.4); 12- month 0 (0--1.8) vs 1.8 (0.17--16); 15-month 7.1 (0--56) vs 2.8 (0.9--18.2)SputumNE reduction after 3-month inhaled gentamicinChalmers, 2012 \[[@CR67]\]ProspectiveMonocentric, outpatientsStable state\
Exacerbation385 Bx patientsElastin-agarose diffusion plate (in-home assay)NE activity (μg x mL): P. aeruginosa infected 4.9 (1.2--68); P. aeruginosa not infected 1.2 (0.4--147.2); other quantitative findings only reported as figuresSputumCorrelation with bacterial load and radiological severityMandall, 2013 \[[@CR73]\]ProspectiveMonocentric, outpatientsStable state163 Bx patientsSpectrophotometryNE activity (U x mL): GERD group 5; non-GERD group 3SputumCorrelation with GERDStockley, 2013 \[[@CR55]\]RCTMulticentric, outpatientsStable state38 Bx patientsCustom-made immunoassay (in-home assay) for both NE and desmosineNE activity AZD9668 group vs placebo (μM x L): baseline 24.54 vs 7.28; end of treatment 15.92 vs 7.49Sputum\
UrineNE reduction after 28-day of oral AZD9668\
No difference in desmosine between AZD9668 and placeboGoeminne, 2014 \[[@CR66]\]Cross-sectionalMonocentric, outpatientsStable state49 Bx patients +12 healthy subjectsEnzymatic assayNE activity (μg x mL): Bx patients 15 (3--23); healthy subject 0.8 (0.4--1.2)SputumCorrelation with TNFA, CXCL8 and MMP-9\
Inverse correlation with FVCLiu, 2014 \[[@CR14]\]RCTMonocentric, outpatientsStable state43 Bx patientsELISA (in-home assay)Quantitative findings only reported as figuresSputumNE reduction after 6-month roxythromicinAliberti, 2016 \[[@CR70]\]ProspectiveMulticentric, outpatientsStable state1145 Bx patientsdifferent assays according to different centersQuantitative findings only reported as figuresSputumCorrelation with '*P. aeruginosa'*cluster and 'Other chronic infection' clusterChalmers, 2016 \[[@CR17]\]ProspectiveStable state\
Exacerbation381 Bx patientsImmunoassay (ProAxsis LTD) Kinetic assay (Sigma Aldrich)\
LC-MS for desmosineNE levels (μg x mL): baseline 0.39 (0--23.5); onset of exacerbation 57.0 (3.3--145); after 14-day atb 0 (0--125.8); 1-month later 1.3 (0--29.9)Sputum\
SerumCorrelation with BSI, MRC, FEV~[1]{.ul}~, bacterial load, radiological severity\
Correlation with higher exacerbation rate, FEV1 decline, all-cause mortality during 3-year follow up\
NE increase during exacerbations and NE reduction after short-term antibiotic therapy\
Serum desmosine is associated with age and disease severityDefinitions: *atb* antibiotics, *A1AT* alpha-1 anti-trypsin, *BAL* broncho-alveolar lavage, *Bx* bronchiectasis, *DES* desmosine, *NE* neutrophil elastase, *SLAPN* succinyl-trialanine-nitroanilide, *SAAVNA* succinyl-Ala-Ala-Val-nitroanilide, *MSAPN* methoxysuccinyl-Ala-Ala-Pro-Val-paranitroanilide, *HPCE* high-performance capillary electrophoresis, *LC-MS* liquid chromatography-mass spectrometry

Discussion {#Sec14}
==========

Clinical relevance of NE role in bronchiectasis has been addressed according to a multidimensional approach: its use as inflammatory biomarkers; potential indicator of severity of disease; predictor of clinical outcomes or response to treatment; target of treatment.

NE as an inflammatory marker {#Sec15}
----------------------------

Patients with clinically stable bronchiectasis exhibit a permanent neutrophilic activation in the airways and display higher sputum levels of NE and others inflammatory mediators than healthy subjects \[[@CR56]--[@CR58]\]. Because of the presence on NE-positive neutrophils in the *lamina propria*, the inflammation is assumed to be driven by NE \[[@CR59]\].

Fujita and Chan demonstrated in different studies that serum levels of NE-A1AT complex in patients with bronchiectasis were significantly higher in comparison to those of healthy subjects suggesting that lung injury is mainly due to NE overexpression than anti-proteinase system deficiency \[[@CR12], [@CR60], [@CR61]\].

Angrill proposed that airway inflammation is permanent and may occur even in the absence of bacterial colonization, as demonstrated by the increase of NE and other inflammatory mediators in the BAL of 49 patients in comparison with healthy subjects \[[@CR62]\]. Previous studies reported that purulent sputum was associated with NE concentration, and can be considered a marker for proteolytic and inflammatory activity \[[@CR18], [@CR63]--[@CR65]\]. These findings were consistent with recent data reported by Goeminne who demonstrated a strong correlation between sputum purulence and proteolytic enzymes, both of which seem to predict the degree of inflammation and disease severity in bronchiectasis \[[@CR66]\].

Moreover, NE has been shown to progressively increase with increasing bacterial load in sputum. Chalmers also reported on a strong association between sputum bacterial load and a cluster of inflammatory mediators in a cohort of 434 bronchiectasis patients \[[@CR16], [@CR67]\]. Finally, high levels of NE have been documented in special phenotypes of bronchiectasis patients, such as those with chronic infection with both *P. aeruginosa* and other bacteria \[[@CR68]--[@CR70]\].

As a marker of airway inflammation, NE also increases during exacerbations and decreases after a short course of oral antibiotic treatment \[[@CR6], [@CR67], [@CR71], [@CR72]\]. These data suggest that NE may act as marker of airway inflammation both in stable patients and during exacerbations.

A correlation between gastroesophageal reflux disease (GERD) and higher levels of NE is also reported \[[@CR73]\].

NE as a predictor of clinical outcomes or response to treatment {#Sec16}
---------------------------------------------------------------

The identification of a biomarker to assess disease severity and predict progression and outcomes is still an unmet need in bronchiectasis \[[@CR51]\]. In the past decades, several experiences showed that NE is associated with clinical outcomes in different bronchiectasis cohorts \[[@CR66], [@CR74], [@CR75]\]. Tsang and coworkers showed a correlation between sputum elastase, radiological involvement, and functional markers in a sample of 30 bronchiectasis patients \[[@CR75]\]. However, the heterogeneity of measurement assays for NE among different cohorts and the lack of relevant follow-up periods may have affected the findings. Recently, NE underwent a prospective validation in a large cohort of patients followed over 3 years. This sample was divided into three groups according to negative, intermediate, and high elastase activity levels. NE activity was independently associated with lung function decline over 3 years with a loss of 56.4 ml per year in the high activity group (+20.8 ml in comparison with negative-NE group). In addition, NE was also independently associated with the risk of future exacerbations, shorter time to next exacerbation, and all-cause mortality \[[@CR17]\].

In a recent evaluation of clinical phenotypes, the phenotype of patients with chronic infection with *P. aeruginosa* or other bacteria was associated with both higher NE concentrations and worse clinical outcome \[[@CR70]\]. This finding is consistent with a meta-analysis by Finch which showed that *P. aeruginosa* chronic infection is associated with a threefold increased risk of death and an increase in hospital admissions and exacerbations \[[@CR76]\].

Future clinical trials are needed to validate cut-off of NE activity and implement NE as a useful biomarker in the clinical management of bronchiectasis patients.

Local or systemic antibiotic therapy and consequent reduction of bacterial load has been hypothesized to decrease sputum NE levels. Previous findings suggest that short oral courses of antibiotic therapy are effective in reducing NE activity in sputum \[[@CR6], [@CR67], [@CR71]\]. Chalmers and Murray proved that long-term nebulized gentamycin significantly reduces free elastase activity in sputum, as well as sputum MPO levels and bacterial load \[[@CR67], [@CR77]\].

Roxithromycin treatment may reduce sputum NE in bronchiectasis patients as recently demonstrated by Liu in an open-label 6-month study. These findings demonstrate that macrolide therapy may be beneficial in bronchiectasis and may contribute to the understanding of underlying mechanisms \[[@CR14], [@CR78]\].

Selected anti-inflammatory drugs have also been tested as indirect modulators of neutrophilic inflammation in bronchiectasis. In a study by Llewellyn-Jones, a 4-week treatment with indomethacin appeared to have no effect on lung inflammation, as assessed by no significant difference in neutrophil and NE activity within the sputum \[[@CR15]\].

NE as a target of treatment {#Sec17}
---------------------------

Since NE is a major driver of neutrophilic inflammation in bronchiectasis, it has been proposed to tailor treatment aimed to its direct or indirect inhibition, see Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Neutrophil elastase: mechanisms of action and treatment targets in bronchiectasis. Definitions: NE = neutrophil elastase; A1AT = alpha-1 anti-trypsin; NSAIDS = non-steroidal anti-inflammatory drugs

AZD9668 is a NE inhibitor previously investigated in chronic respiratory diseases, including COPD and CF, with inconclusive results \[[@CR34], [@CR44], [@CR45]\]. In a small phase II double-blind trial conducted in 10 different centres, 38 patients were randomized to 4 weeks of oral AZD9668 twice daily. AZD9668 increased FEV~1~ (by about 100 mL) and slowed vital capacity (by about 130 mL) compared with the placebo group. A trend in reduction of most inflammatory biomarkers was also reported (IL-6 and IL-8). There were no differences between AZD9668 and placebo arms regarding sputum quantity, symptoms, and quality of life. The Authors suggested larger studies of longer duration to assess beneficial effects \[[@CR55], [@CR79]\].

BAY 85--8501 is a selective NE inhibitor that has shown efficacy in pre-clinical pharmacological and animal models \[[@CR80]\]. A phase II randomized parallel group study assessed the safety and tolerability of 28-day oral administration of BAY 85--8501 in 94 bronchiectasis patients. BAY 85--8501 was generally well tolerated and there were no significant changes in lung function, 24 h sputum quantity, NE activity and concentration, and other biomarkers including urine desmosine \[[@CR81]\]. Short duration of treatment and inadequate drug concentration at the target site may be the cause of this lack of efficacy. Regarding this last point, it is reasonable that the inhaled approach instead of the oral administration could allow reaching higher lung concentrations with limited systemic exposure and consequent side effects, thus permitting to counteract that elevated amount of active NE found in the patient's airways.

With this rationale, CHF6333 is the first inhaled NE inhibitor under development for the treatment of NE-driven lung diseases as dry powder inhaler. In in vitro assays, CHF6333 is highly potent in inhibiting human NE (IC~50~ = 0.2 nM) with good selectivity against other proteases. In addition, CHF6333 significantly reduces lung neutrophil recruitment induced by cigarette smoke exposure in mice and reduces both lung tissue infection and inflammation when administered intratracheally to *P. aeruginosa* lung infected rats for 7 days \[[@CR82]\].

A phase I trial to investigate safety and pharmacokinetics on healthy male subjects is still in phase of recruitment ([clinicaltrial.gov](http://clinicaltrial.gov) ID NCT03056326).

Conclusions {#Sec18}
===========

Sputum NE has proved useful as an inflammatory marker both in stable state bronchiectasis and during exacerbations and local or systemic antibiotic treatment. NE has also been associated with risk of exacerbation, time to next exacerbation and all-cause mortality. Inhibition of NE as a specific target of treatment in bronchiectasis is at a very early stage. Future interventional studies should evaluate safety and efficacy for new molecules and formulations.
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